Transarterial chemoembolization combined with radiofrequency ablation in the treatment of hepatocell

• 作 者: Yi Yang Zhuo-Min Lv Min Yan Hong-Xin Zhang Yong Long Wei-Lu Zhang
• 机 构: Department of Pain Treatment, Tangdu Hospital of the Fourth Military Medical University, Xi’an 71003
• 出 处: 肝癌研究（英文版）
• 发表日期: 2019年4期
• 关键词: Transarterial chemoembolization radiofrequency ablation hepatocellular carcinoma

Aim: This meta-analysis was designed to compare the effectiveness of the combination of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) vs. that of TACE alone in hepatocellular carcinoma (HCC) tumors larger than 5 cm. Methods: PUBMED, CNKI, and CBM were searched for all related randomized controlled trials (RCTs) up until October 22, 2018. Eleven studies were identified that compared TACE with RFAvs. TACE alone for HCC treatment. Tumor response rate, the proportion of patients with either complete or partial shrinkage of tumors, and survival rate were the major evaluation indices. Results: Meta-analysis data revealed that TACE with RFA showed significantly better tumor response rate (risk ratio (RR) = 1.452, 95％ confidence interval (CI): 1.308-1.610,P < 0.001) and 1-year overall survival rate (RR = 1.412, 95％CI: 1.249-1.596,P < 0.001) than that of TACE alone treatment. Conclusion: The data of our study indicates that TACE combined with RFA in the treatment of HCC larger than 5 cm is an effective comprehensive interventional therapy.